Therefore, the therapeutic use of STAT/JAK-modulators should be carefully evaluated for their specific targeting of STAT3 activity while preserving IFNγ-induced STAT1/2 signaling, which appears to be beneficial for anti-tumor immune responses. The gene discussed is STAT3; the disease is neoplasm.